Objective Patients with peripheral artery disease (PAD) are at increased risk of major
adverse limb events (MALE). Furthermore, MALE have several clinical implications and a …

Background Lipid‐lowering therapy is recommended for secondary prevention in people
with coronary artery disease. It may also reduce cardiovascular events and/or local disease …

OBJECTIVE To determine the proportion of patients with lower extremity peripheral arterial
disease (PAD) who reach recommended low-density lipoprotein cholesterol (LDL-C) levels …

Effective methods to educate physicians and patients on best medical management are
needed. Further research is needed to examine the benefit of LDL-c lowering and other lipid …

Background Statins are guidelines recommended in patients with peripheral artery disease
(PAD) for the prevention of cardiovascular (CV) events. Comprehensive meta-data on the …

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and is
associated with high mortality due to cardiovascular events. As lipid-lowering therapy has …

Abstract Purpose of Review There is a lack of consistency among the ACC/AHA and ESC
Guidelines on the treatment of patients with lower extremity PAD to a targeted LDL-c level. A …

Peripheral arterial disease (PAD) is a common disorder usually associated with silent or
symptomatic arterial disease elsewhere in the circulation and a “cluster” of cardiovascular …

Objective Individual studies of peripheral artery disease (PAD) have indicated that gender
discrepancies exist in the symptoms, functional status, and treatment usage. It remains …

BACKGROUND: Patients affected by peripheral arterial disease (PAD) incur a heightened
risk of adverse cardiovascular events, including stroke, myocardial infarction, and vascular …